Hikma Pharmaceuticals PLC (HKMPF)
Hikma Pharmaceuticals PLC operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $22.28, up 0.00% on the session, giving a market capitalisation of $4.65B. On trailing twelve-month figures it carries a trailing P/E of 12.41, a net margin of 11.3%. Its beta of 0.65 implies it has historically moved less than the broad market.
Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spanning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.
Hikma Pharmaceuticals PLC is most often compared with the following Healthcare names: